CAPR Capricor Therapeutics, Inc.
Healthcare$28.87-2.40%ClosedMarket Cap: $1.32B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
5.95
P/S
0.00
EV/EBITDA
-10.54
DCF Value
$5.71
FCF Yield
-8.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-59.3%
ROA
-35.1%
ROIC
-40.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-36.8M | $-33.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-29.2M | $-30.2M | $— | — |
| FY null | $0.00 | NaN% | $-108.1M | $-105.0M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-26.3M | $-24.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-27.7M | $-25.9M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-25.0M | $-24.4M | $— | — |
| Q4 null | $11.1M | -30.8% | $-7.7M | $-7.1M | $— | — |
| FY null | $22.3M | -124.4% | $-42.6M | $-40.5M | $— | — |
| Q3 null | $2.3M | -422.1% | $-13.0M | $-12.6M | $— | — |
| Q2 null | $4.0M | -214.9% | $-11.6M | $-11.0M | $— | — |
| Q1 null | $4.9M | -126.2% | $-10.3M | $-9.8M | $— | — |
| Q4 2023 | $12.1M | 17.8% | $-1.3M | $-762.1K | $-0.02 | — |